This inventor holds 2 USPTO granted patents and 7 published patent applications and 3 EPO patents. Top assignee: Previpharma Consulting Gmbh. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Title: The Innovations of Stephan T Kiessig
Introduction
Stephan T Kiessig is a notable inventor based in Wiesloch, Germany. He has made significant contributions to the field of medical science, particularly in the treatment of lung dysfunction and related disorders. With a total of 2 patents, his work is recognized for its potential impact on patient care.
Latest Patents
Kiessig's latest patents include innovative methods for utilizing plasminogen in medical treatments. The first patent focuses on plasminogen for use in treating and preventing lung dysfunction associated with the formation of hyaline membranes in patients. This invention emphasizes the administration of plasminogen activators alongside plasminogen to enhance treatment efficacy. The second patent details the preparation and use of Glu-plasminogen derived from blood fractions. This method involves anion exchange chromatography to isolate Glu-plasminogen, which can be used to treat patients at risk of various disorders, including organ failure and thrombotic events.
Career Highlights
Kiessig is currently associated with Previpharma Consulting GmbH, where he continues to develop and refine his innovative ideas. His work is characterized by a commitment to advancing medical treatments and improving patient outcomes.
Collaborations
Throughout his career, Kiessig has collaborated with talented professionals, including Ricarda Welz and Hanne Rieke Gerding. These partnerships have contributed to the development of his groundbreaking inventions.
Conclusion
Stephan T Kiessig's contributions to medical science through his patents demonstrate his dedication to innovation and improving healthcare. His work has the potential to significantly impact the treatment of lung dysfunction and related disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile